Literature DB >> 2299679

Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors.

F L Moolten1, J M Wells.   

Abstract

Retroviral vectors constructed to contain the herpes simplex virus thymidine kinase (HSV-TK) gene were used for transduction of this gene into murine sarcoma and lymphoma cells to yield sublines susceptible in vitro to the cytotoxicity of ganciclovir, a drug specifically activated by HSV-TK. In vivo, ganciclovir induced complete, durable regressions in most mice bearing transplanted HSV-TK-positive sarcomas; its efficacy against lymphomas was only marginal, possibly because of their greater instability of gene expression. The results imply the potential value of an anticancer strategy entailing the prophylactic use of retroviral vectors to create tissue mosaicism for drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299679     DOI: 10.1093/jnci/82.4.297

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  73 in total

Review 1.  Imaging transgene expression with radionuclide imaging technologies.

Authors:  S S Gambhir; H R Herschman; S R Cherry; J R Barrio; N Satyamurthy; T Toyokuni; M E Phelps; S M Larson; J Balatoni; R Finn; M Sadelain; J Tjuvajev; R Blasberg
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Therapeutic genes for cancer gene therapy.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

3.  Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.

Authors:  Michael D Prados; Michael McDermott; Susan M Chang; Charles B Wilson; James Fick; Kenneth W Culver; John Van Gilder; G Evren Keles; Alex Spence; Mitchel Berger
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

4.  Fabrication of a DNA-lipid-apatite composite layer for efficient and area-specific gene transfer.

Authors:  Ayako Oyane; Yushin Yazaki; Hiroko Araki; Yu Sogo; Atsuo Ito; Atsushi Yamazaki; Hideo Tsurushima
Journal:  J Mater Sci Mater Med       Date:  2012-02-25       Impact factor: 3.896

5.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.

Authors:  J G Julias; D Hash; V K Pathak
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

Authors:  J Fick; F G Barker; P Dazin; E M Westphale; E C Beyer; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.

Authors:  D Barba; J Hardin; M Sadelain; F H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Ganciclovir mediated regression of rat brain tumors expressing the herpes simplex virus thymidine kinase imaged by magnetic resonance.

Authors:  A Maron; T Gustin; I Mottet; R Demeure; J N Octave
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas.

Authors:  Prakash Rath; Huidong Shi; Joel A Maruniak; N Scott Litofsky; Bernard L Maria; Mark D Kirk
Journal:  Curr Stem Cell Res Ther       Date:  2009-01       Impact factor: 3.828

10.  Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.

Authors:  W R Smythe; H C Hwang; A A Elshami; K M Amin; S L Eck; B L Davidson; J M Wilson; L R Kaiser; S M Albelda
Journal:  Ann Surg       Date:  1995-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.